Humacyte to Present at the Jefferies Global Healthcare Conference
Humacyte will present at the Jefferies Global Healthcare Conference on June 6, 2024, in New York, NY. The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will lead the presentation at 1:00 p.m. ET. Humacyte specializes in developing bioengineered human tissues and aims to share significant updates and engage in one-on-one meetings. The event will be held at the Marriott Marquis, and a webcast will be available for a time on Humacyte's website.
- Humacyte to participate in the prestigious Jefferies Global Healthcare Conference.
- Presentation led by Laura Niklason, M.D., Ph.D., Founder, President, and CEO, enhancing credibility.
- Opportunity for one-on-one meetings to foster investor relations and potential partnerships.
- Webcast availability for broader investor access.
- No specific new financial or clinical updates announced in the PR.
- time availability for the webcast replay may restrict access for some investors.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, in New York, NY on Thursday, June 6, 2024. Management will also be available for one-on-one meetings.
Event: Jefferies Global Healthcare Conference
Location: Marriott Marquis, New York, NY
Presentation: Thursday, June 6, 1:00 p.m. ET
Webcast: https://pay.twstevents.com/webcasting/jeff302
A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Humacyte website.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. In February 2024 the Food and Drug Administration (FDA) accepted Humacyte’s Biologics License Application (BLA) seeking approval of the HAV in the vascular trauma indication and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) date of August 10, 2024, Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte present at the Jefferies Global Healthcare Conference?
Where is the Jefferies Global Healthcare Conference held?
Who is presenting on behalf of Humacyte at the Jefferies Global Healthcare Conference?
Will there be a webcast available for Humacyte's presentation?
